Grail, Inc. (NASDAQ:GRAL) Short Interest Update

Grail, Inc. (NASDAQ:GRAL) was the recipient of a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 4,900,000 shares, a growth of 11.9% from the November 30th total of 4,380,000 shares. Currently, 17.0% of the shares of the company are short sold. Based on an average daily trading volume, of 800,300 shares, the days-to-cover ratio is presently 6.1 days.

Insider Activity

In related news, CFO Aaron Freidin sold 30,452 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $14.02, for a total transaction of $426,937.04. Following the completion of the sale, the chief financial officer now directly owns 268,277 shares in the company, valued at approximately $3,761,243.54. The trade was a 10.19 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Chun R. Ding purchased 7,629 shares of the firm’s stock in a transaction on Tuesday, October 1st. The stock was acquired at an average price of $13.52 per share, for a total transaction of $103,144.08. Following the completion of the transaction, the insider now directly owns 3,503,655 shares of the company’s stock, valued at approximately $47,369,415.60. This trade represents a 0.22 % increase in their position. The disclosure for this purchase can be found here. Insiders have bought 58,829 shares of company stock valued at $757,298 in the last ninety days.

Analyst Ratings Changes

Several research firms have recently commented on GRAL. Wolfe Research began coverage on Grail in a research note on Friday, November 15th. They issued a “peer perform” rating on the stock. Guggenheim began coverage on shares of Grail in a research note on Thursday, October 17th. They issued a “neutral” rating for the company. Finally, Morgan Stanley started coverage on shares of Grail in a research note on Wednesday, November 27th. They set an “equal weight” rating and a $16.00 target price on the stock.

Grail Price Performance

GRAL stock traded down $0.69 during midday trading on Monday, hitting $18.91. The company’s stock had a trading volume of 405,438 shares, compared to its average volume of 1,078,906. Grail has a 12 month low of $12.33 and a 12 month high of $24.92. The business has a 50 day moving average price of $17.02.

Grail Company Profile

GRAIL, Inc, a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer.